

# Dudley J Pennell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/250159/publications.pdf>

Version: 2024-02-01

249  
papers

27,589  
citations

12322

69  
h-index

5532

163  
g-index

271  
all docs

271  
docs citations

271  
times ranked

16649  
citing authors

#	ARTICLE	IF	CITATIONS
1	Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart. <i>Circulation</i> , 2002, 105, 539-542.	1.6	5,371
2	Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. <i>American Journal of Cardiology</i> , 2002, 90, 29-34.	0.7	1,259
3	Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) Board of Trustees Task Force on Standardized Post Processing. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2013, 15, 35.	1.6	1,037
4	Cardiovascular Magnetic Resonance, Fibrosis, and Prognosis in Dilated Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1977-1985.	1.2	1,026
5	A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. <i>Journal of Magnetic Resonance Imaging</i> , 2003, 18, 33-39.	1.9	741
6	Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. <i>American Heart Journal</i> , 2004, 147, 218-223.	1.2	686
7	Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report?. <i>European Heart Journal</i> , 2004, 25, 1940-1965.	1.0	649
8	The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2004, 43, 2260-2264.	1.2	628
9	Left-Dominant Arrhythmogenic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2008, 52, 2175-2187.	1.2	590
10	Reduction in Sample Size for Studies of Remodeling in Heart Failure by the Use of Cardiovascular Magnetic Resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2000, 2, 271-278.	1.6	583
11	Ventricular Fibrosis Suggested by Cardiovascular Magnetic Resonance in Adults With Repaired Tetralogy of Fallot and Its Relationship to Adverse Markers of Clinical Outcome. <i>Circulation</i> , 2006, 113, 405-413.	1.6	536
12	Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance. <i>European Heart Journal</i> , 2006, 27, 2879-2888.	1.0	490
13	Black-blood T2* technique for myocardial iron measurement in thalassemia. <i>Journal of Magnetic Resonance Imaging</i> , 2007, 25, 1205-1209.	1.9	489
14	Myocardial $T_2^*$ measurement in iron-overloaded thalassemia: An ex vivo study to investigate optimal methods of quantification. <i>Magnetic Resonance in Medicine</i> , 2008, 60, 350-356.	1.9	473
15	Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2008, 10, 42.	1.6	469
16	Standardized image interpretation and post-processing in cardiovascular magnetic resonance - 2020 update. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2020, 22, 19.	1.6	467
17	Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. <i>Blood</i> , 2006, 107, 3738-3744.	0.6	424
18	Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. <i>Lancet</i> , The, 2002, 360, 516-520.	6.3	394

#	ARTICLE	IF	CITATIONS
19	On T2* Magnetic Resonance and Cardiac Iron. <i>Circulation</i> , 2011, 123, 1519-1528.	1.6	381
20	Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. <i>Lancet</i> , The, 2019, 393, 61-73.	6.3	379
21	Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 171, 1292-1297.	2.5	345
22	Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. <i>British Journal of Haematology</i> , 2004, 127, 348-355.	1.2	340
23	Cardiovascular Function and Treatment in $\hat{\text{T}}^2$ -Thalassemia Major. <i>Circulation</i> , 2013, 128, 281-308.	1.6	301
24	Breath-hold FLASH and FISP Cardiovascular MR Imaging: Left Ventricular Volume Differences and Reproducibility. <i>Radiology</i> , 2002, 223, 789-797.	3.6	270
25	The Prevalence and Prognostic Significance of Right Ventricular Systolic Dysfunction in Nonischemic Dilated Cardiomyopathy. <i>Circulation</i> , 2013, 128, 1623-1633.	1.6	265
26	Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction. <i>Circulation</i> , 2017, 135, 2106-2115.	1.6	265
27	Late Gadolinium Enhancement Cardiovascular Magnetic Resonance of the Systemic Right Ventricle in Adults With Previous Atrial Redirection Surgery for Transposition of the Great Arteries. <i>Circulation</i> , 2005, 111, 2091-2098.	1.6	260
28	Assessment of Left Ventricular Mass by Cardiovascular Magnetic Resonance. <i>Hypertension</i> , 2002, 39, 750-755.	1.3	256
29	Cardiovascular Magnetic Resonance. <i>Circulation</i> , 2010, 121, 692-705.	1.6	244
30	Magnetic resonance imaging during dobutamine stress in coronary artery disease. <i>American Journal of Cardiology</i> , 1992, 70, 34-40.	0.7	216
31	Reference left atrial dimensions and volumes by steady state free precession cardiovascular magnetic resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2010, 12, 65.	1.6	209
32	Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2008, 10, 12.	1.6	195
33	MR navigator-echo monitoring of temporal changes in diaphragm position: Implications for MR coronary angiography. <i>Journal of Magnetic Resonance Imaging</i> , 1997, 7, 629-636.	1.9	189
34	Outcome in Dilated Cardiomyopathy Related to the Extent, Location, and Pattern of Late Gadolinium Enhancement. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1645-1655.	2.3	187
35	MR Imaging of Arrhythmogenic Right Ventricular Cardiomyopathy: Morphologic Findings and Interobserver Reliability. <i>Cardiology</i> , 2003, 99, 153-162.	0.6	179
36	Assessment of Myocardial Microstructural Dynamics by In Vivo Diffusion Tensor Cardiac Magnetic Resonance. <i>Journal of the American College of Cardiology</i> , 2017, 69, 661-676.	1.2	171

#	ARTICLE	IF	CITATIONS
37	SCMR Position Paper (2020) on clinical indications for cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2020, 22, 76.	1.6	169
38	Efficacy of deferasirox in reducing and preventing cardiac iron overload in $\beta^2$ -thalassemia. Blood, 2010, 115, 2364-2371.	0.6	168
39	Clinical Outcomes of Surgical Pulmonary Valve Replacement After Repair of Tetralogy of Fallot and Potential Prognostic Value of Preoperative Cardiopulmonary Exercise Testing. Circulation, 2014, 129, 18-27.	1.6	151
40	Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia. Journal of Magnetic Resonance Imaging, 2003, 18, 616-620.	1.9	149
41	T2* Magnetic Resonance and Myocardial Iron in Thalassemia. Annals of the New York Academy of Sciences, 2005, 1054, 373-378.	1.8	148
42	In vivo diffusion tensor MRI of the human heart: Reproducibility of breathhold and navigator-based approaches. Magnetic Resonance in Medicine, 2013, 70, 454-465.	1.9	145
43	Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart, 2014, 100, 1851-1858.	1.2	144
44	Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography. Journal of Magnetic Resonance Imaging, 1999, 9, 220-227.	1.9	141
45	Role of Magnetic Resonance Angiography in the Diagnosis of Major Aortopulmonary Collateral Arteries and Partial Anomalous Pulmonary Venous Drainage. Circulation, 2004, 109, 207-214.	1.6	141
46	Ventricular Volume and Mass by CMR. Journal of Cardiovascular Magnetic Resonance, 2003, 4, 507-513.	1.6	139
47	International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. Journal of Magnetic Resonance Imaging, 2010, 32, 315-319.	1.9	139
48	In vivo cardiovascular magnetic resonance diffusion tensor imaging shows evidence of abnormal myocardial laminar orientations and mobility in hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 87.	1.6	137
49	Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart. Journal of Cardiovascular Magnetic Resonance, 2002, 4, 203-210.	1.6	132
50	Myocardial $T_2^*$ measurements in iron-overloaded thalassemia: An in vivo study to investigate optimal methods of quantification. Magnetic Resonance in Medicine, 2008, 60, 1082-1089.	1.9	132
51	Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with $\beta^2$ -thalassemia major. Haematologica, 2012, 97, 842-848.	1.7	122
52	Role of Cardiovascular Magnetic Resonance as a Gatekeeper to Invasive Coronary Angiography in Patients Presenting With Heart Failure of Unknown Etiology. Circulation, 2011, 124, 1351-1360.	1.6	113
53	Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica, 2006, 91, 1388-91.	1.7	113
54	Echo-planar magnetic resonance myocardial perfusion imaging: Parametric map analysis and comparison with thallium SPECT. Journal of Magnetic Resonance Imaging, 2001, 13, 192-200.	1.9	105

#	ARTICLE	IF	CITATIONS
55	Intercentre Reproducibility of Magnetic Resonance T2* Measurements of Myocardial Iron in Thalassemia. <i>International Journal of Cardiovascular Imaging</i> , 2005, 21, 531-538.	0.7	104
56	A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in $\beta^2$ -thalassemia major (CORDELIA). <i>Blood</i> , 2014, 123, 1447-1454.	0.6	97
57	Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. <i>British Journal of Haematology</i> , 2007, 138, 587-593.	1.2	92
58	Mechanisms of Myocardial Ischemia in Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1651-1660.	1.2	92
59	Sex- and age-based differences in the natural history and outcome of dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2018, 20, 1392-1400.	2.9	92
60	Phenotype and Clinical Outcomes of Titin Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2264-2274.	1.2	86
61	Establishment and Performance of a Magnetic Resonance Cardiac Function Clinic. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2000, 2, 15-22.	1.6	84
62	Immediate and Midterm Cardiac Remodeling After Surgical Pulmonary Valve Replacement in Adults With Repaired Tetralogy of Fallot. <i>Circulation</i> , 2017, 136, 1703-1713.	1.6	84
63	Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. <i>Journal of Magnetic Resonance Imaging</i> , 2007, 25, 1147-1151.	1.9	81
64	Cardiovascular Magnetic Resonance for Patients With COVID-19. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 685-699.	2.3	79
65	Reproducibility of in-vivo diffusion tensor cardiovascular magnetic resonance in hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2012, 14, 86.	1.6	78
66	An in-vivo comparison of stimulated-echo and motion compensated spin-echo sequences for 3T diffusion tensor cardiovascular magnetic resonance at multiple cardiac phases. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2018, 20, 1.	1.6	78
67	Systemic Right Ventricular Fibrosis Detected by Cardiovascular Magnetic Resonance Is Associated With Clinical Outcome, Mainly New-Onset Atrial Arrhythmia, in Patients After Atrial Redirection Surgery for Transposition of the Great Arteries. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, .	1.3	74
68	Quantification of Right and Left Ventricular Function by Cardiovascular Magnetic Resonance. <i>Herz</i> , 2000, 25, 392-399.	0.4	73
69	Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major. <i>Journal of Magnetic Resonance Imaging</i> , 2005, 22, 229-233.	1.9	73
70	Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial. <i>European Heart Journal</i> , 2017, 38, 1561-1569.	1.0	71
71	Continued improvement in myocardial T2* over two years of deferasirox therapy in $\beta^2$ -thalassemia major patients with cardiac iron overload. <i>Haematologica</i> , 2011, 96, 48-54.	1.7	70
72	Differences between normal subjects and patients with coronary artery disease for three different MR coronary angiography respiratory suppression techniques. <i>Journal of Magnetic Resonance Imaging</i> , 1999, 9, 786-793.	1.9	66

#	ARTICLE	IF	CITATIONS
73	Cardiovascular magnetic resonance: twenty-first century solutions in cardiology. <i>Clinical Medicine</i> , 2003, 3, 273-278.	0.8	66
74	Left ventricular function and mass after orthotopic heart transplantation: a comparison of cardiovascular magnetic resonance with echocardiography. <i>Journal of Heart and Lung Transplantation</i> , 2000, 19, 444-452.	0.3	65
75	International survey of T2* cardiovascular magnetic resonance in $\hat{A}$ -thalassemia major. <i>Haematologica</i> , 2013, 98, 1368-1374.	1.7	62
76	Renal denervation in heart failure with preserved ejection fraction (<sc>RDTa€PEF</sc>): a randomized controlled trial. <i>European Journal of Heart Failure</i> , 2016, 18, 703-712.	2.9	62
77	Prevalence and distribution of iron overload in patients with transfusionâ€dependent anemias differs across geographic regions: results from the <sc>CORDELIA</sc> study. <i>European Journal of Haematology</i> , 2015, 95, 244-253.	1.1	61
78	Long term effects of cocaine on the heart assessed by cardiovascular magnetic resonance at 3T. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2014, 16, 26.	1.6	60
79	CMR GuidanceÂforÂRecanalization of CoronaryÂChronicÂTotal Occlusion. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 547-556.	2.3	60
80	Right atrial area and right ventricular outflow tract akinetic length predict sustained tachyarrhythmia in repaired tetralogy of Fallot. <i>International Journal of Cardiology</i> , 2013, 168, 3280-3286.	0.8	59
81	Hybrid ordered phase encoding (HOPE): An improved approach for respiratory artifact reduction. <i>Journal of Magnetic Resonance Imaging</i> , 1998, 8, 968-980.	1.9	55
82	Microvascular Dysfunction in DilatedÂCardiomyopathy. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1699-1708.	2.3	49
83	Characterization of left and right atrial function in healthy volunteers by cardiovascular magnetic resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 18, 64.	1.6	48
84	The role of cardiovascular magnetic resonance in heart failure. <i>European Journal of Heart Failure</i> , 2000, 2, 241-252.	2.9	47
85	Training and accreditation in cardiovascular magnetic resonance in Europe: a position statement of the working group on cardiovascular magnetic resonance of the European Society of Cardiology. <i>European Heart Journal</i> , 2011, 32, 793-798.	1.0	46
86	Comparison of 3ÂT and 1.5ÂT for T2* magnetic resonance of tissue iron. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 18, 40.	1.6	46
87	Optimal diffusion weighting for in vivo cardiac diffusion tensor imaging. <i>Magnetic Resonance in Medicine</i> , 2015, 74, 420-430.	1.9	45
88	Diffusion Tensor Cardiovascular Magnetic Resonance Imaging. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1235-1255.	2.3	45
89	Sustained improvements in myocardial T2* over 2 years in severely ironâ€overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. <i>American Journal of Hematology</i> , 2015, 90, 91-96.	2.0	43
90	Myocardial Fibrosis in Glycogen Storage Disease Type III. <i>Circulation</i> , 2003, 107, e47.	1.6	42

#	ARTICLE	IF	CITATIONS
91	Absence of Myocardial Fibrosis Predicts Favorable Long-Term Survival in New-Onset Heart Failure. Circulation: Cardiovascular Imaging, 2018, 11, e007722.	1.3	42
92	Value of black blood T2* cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 21.	1.6	41
93	T1 at 1.5T and 3T compared with conventional T2* at 1.5T for cardiac siderosis. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 102.	1.6	40
94	First-pass myocardial perfusion imaging and equilibrium signal changes using the intravascular contrast agent NC100150 injection. Journal of Magnetic Resonance Imaging, 1999, 10, 404-410.	1.9	39
95	Predicting Survival in Repaired Tetralogy of Fallot. JACC: Cardiovascular Imaging, 2022, 15, 257-268.	2.3	37
96	Left ventricular quantification in heart failure by cardiovascular MR using prospective respiratory navigator gating: Comparison with breath-hold acquisition. Journal of Magnetic Resonance Imaging, 2000, 11, 411-417.	1.9	35
97	Relation of myocardial T2* to right ventricular function in thalassaemia major. European Heart Journal, 2010, 31, 1648-1654.	1.0	35
98	Neurohormonal activation and its relation to outcomes late after repair of tetralogy of Fallot. Heart, 2015, 101, 447-454.	1.2	34
99	Intercentre reproducibility of cardiac apparent diffusion coefficient and fractional anisotropy in healthy volunteers. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 31.	1.6	33
100	The effects of noise in cardiac diffusion tensor imaging and the benefits of averaging complex data. NMR in Biomedicine, 2016, 29, 588-599.	1.6	32
101	Automated monitoring of diaphragm end-expiratory position for real-time navigator echo MR coronary angiography. Journal of Magnetic Resonance Imaging, 1999, 9, 395-401.	1.9	31
102	A comparison between segmented k-space FLASH and interleaved spiral MR coronary angiography sequences. Journal of Magnetic Resonance Imaging, 2000, 11, 394-400.	1.9	31
103	Electrocardiographic (ECG) criteria for determining left ventricular mass in young healthy men; data from the LARGE Heart study. Journal of Cardiovascular Magnetic Resonance, 2009, 11, 2.	1.6	31
104	Magnetic resonance navigator echo diaphragm monitoring in patients with suspected diaphragm paralysis. Journal of Magnetic Resonance Imaging, 1999, 9, 69-74.	1.9	29
105	Cardiac complications in thalassemia major. Annals of the New York Academy of Sciences, 2016, 1368, 56-64.	1.8	29
106	Cardiovascular magnetic resonance and the role of adenosine pharmacologic stress. American Journal of Cardiology, 2004, 94, 26-31.	0.7	28
107	Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 8.	1.6	28
108	Cardiovascular magnetic resonance normal values in children for biventricular wall thickness and mass. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 1.	1.6	28

#	ARTICLE	IF	CITATIONS
109	Cardiac Diffusion: Technique and Practical Applications. Journal of Magnetic Resonance Imaging, 2020, 52, 348-368.	1.9	27
110	Comparison of equilibrium radionuclide ventriculography with cardiovascular magnetic resonance for assessing the systemic right ventricle after Mustard or Senning procedures for complete transposition of the great arteries. American Journal of Cardiology, 2003, 92, 640-643.	0.7	26
111	Major adverse events and atrial tachycardia in Ebstein's anomaly predicted by cardiovascular magnetic resonance. Heart, 2018, 104, 37-44.	1.2	26
112	Heterogeneity of Fractional Anisotropy and Mean Diffusivity Measurements by In Vivo Diffusion Tensor Imaging in Normal Human Hearts. PLoS ONE, 2015, 10, e0132360.	1.1	26
113	Three-Dimensional Late Gadolinium Enhancement Cardiovascular Magnetic Resonance Predicts Inducibility of Ventricular Tachycardia in Adults With Repaired Tetralogy of Fallot. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008321.	2.1	25
114	Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer. PLoS ONE, 2016, 11, e0165262.	1.1	24
115	Automated truncation method for myocardial T2* measurement in thalassemia. Journal of Magnetic Resonance Imaging, 2013, 37, 479-483.	1.9	23
116	Improved Myocardial T2* in Transfusion Dependent Anemias Receiving ICL670 (Deferasirox).. Blood, 2005, 106, 3600-3600.	0.6	23
117	T2* cardiovascular magnetic resonance in the management of thalassemia patients in Oman. Haematologica, 2009, 94, 140-141.	1.7	22
118	Evidence to support magnetic resonance conditional labelling of all pacemaker and defibrillator leads in patients with cardiac implantable electronic devices. European Heart Journal, 2022, 43, 2469-2478.	1.0	22
119	Stochastic Deep Compressive Sensing for the Reconstruction of Diffusion Tensor Cardiac MRI. Lecture Notes in Computer Science, 2018, , 295-303.	1.0	22
120	Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging. Hematology, 2017, 22, 1-7.	0.7	21
121	Comparison of fast spiral, echo planar, and fast low-angle shot MRI for cardiac volumetry at .5T. Journal of Magnetic Resonance Imaging, 1998, 8, 1033-1039.	1.9	20
122	On using $T_2^*$ to assess extrinsic magnetic field inhomogeneity effects on $T_2^*$ measurements in myocardial siderosis in thalassemia. Magnetic Resonance in Medicine, 2009, 61, 501-506.	1.9	20
123	Clinical value of cardiovascular magnetic resonance in patients with MR-conditional pacemakers. European Heart Journal Cardiovascular Imaging, 2016, 17, 1178-1185.	0.5	19
124	Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy: insights from TREDHF. European Journal of Heart Failure, 2021, 23, 293-301.	2.9	19
125	Magnetic resonance imaging phantoms for quality-control of myocardial T1 and ECV mapping: specific formulation, long-term stability and variation with heart rate and temperature. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 62.	1.6	18
126	Effect of Pregnancy on Ventricular and Aortic Dimensions in Repaired Tetralogy of Fallot. Journal of the American Heart Association, 2017, 6, .	1.6	18



#	ARTICLE	IF	CITATIONS
127	Diffusion Tensor Cardiovascular Magnetic Resonance of Microstructural Recovery in Dilated Cardiomyopathy. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1548-1550.	2.3	18
128	Evaluation of the impact of strain correction on the orientation of cardiac diffusion tensors with in vivo and ex vivo porcine hearts. <i>Magnetic Resonance in Medicine</i> , 2018, 79, 2205-2215.	1.9	18
129	Low prevalence of cardiac siderosis in heavily iron loaded Egyptian thalassemia major patients. <i>Annals of Hematology</i> , 2014, 93, 375-379.	0.8	17
130	The evolving role of cardiac magnetic resonance in primary mitral regurgitation: ready for prime time?. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 123-130.	0.5	17
131	Evaluation of free-breathing three-dimensional magnetic resonance coronary angiography with hybrid ordered phase encoding (HOPE) for the detection of proximal coronary artery stenosis. <i>Journal of Magnetic Resonance Imaging</i> , 2001, 14, 677-684.	1.9	16
132	Prevalence and Prognostic Significance of Right Ventricular Systolic Dysfunction in Patients Undergoing Transcatheter Aortic Valve Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	16
133	Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2010, 12, 24.	1.6	15
134	Value of Formalin Fixation for the Prolonged Preservation of Rodent Myocardial Microanatomical Organization: Evidence by MR Diffusion Tensor Imaging. <i>Anatomical Record</i> , 2016, 299, 878-887.	0.8	15
135	Deranged Myocyte Microstructure in Situs Inversus Totalis Demonstrated by Diffusion Tensor Cardiac Magnetic Resonance. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1360-1362.	2.3	15
136	Automating in vivo cardiac diffusion tensor postprocessing with deep learning-based segmentation. <i>Magnetic Resonance in Medicine</i> , 2020, 84, 2801-2814.	1.9	15
137	Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. <i>Lancet, The</i> , 2003, 361, 183-184.	6.3	14
138	Cardiovascular Magnetic Resonance in the Evaluation of Hypertrophic and Infiltrative Cardiomyopathies. <i>Heart Failure Clinics</i> , 2009, 5, 369-387.	1.0	14
139	Post-mortem study of the association between cardiac iron and fibrosis in transfusion dependent anaemia. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 19, 36.	1.6	14
140	Ramipril and left ventricular diastolic function in stable patients with pulmonary regurgitation after repair of tetralogy of Fallot. <i>International Journal of Cardiology</i> , 2018, 272, 64-69.	0.8	14
141	Late-Gadolinium Enhancement Interface Area and Electrophysiological Simulations Predict Arrhythmic Events in Patients With Nonischemic Dilated Cardiomyopathy. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 238-249.	1.3	13
142	Impact of Compliance, Ferritin and LIC on Long-Term Trends in Myocardial T2* with Deferasirox. <i>Blood</i> , 2008, 112, 116-116.	0.6	13
143	Society for Cardiovascular Magnetic Resonance (SCMR) guidelines for reporting cardiovascular magnetic resonance examinations. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2022, 24, 29.	1.6	13
144	Efficacy and Safety of Deferasirox (Exjade®) in Reducing Cardiac Iron in Patients with $\beta^2$ -Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial. <i>Blood</i> , 2008, 112, 3873-3873.	0.6	12

#	ARTICLE	IF	CITATIONS
145	A Decade Follow-up of a Thalassemia Major (TM) Cohort Monitored by Cardiac Magnetic Resonance Imaging (CMR): Significant Reduction In Patients with Cardiac Iron and In Total Mortality. <i>Blood</i> , 2010, 116, 1011-1011.	0.6	12
146	Cardiovascular Magnetic Resonance Determinants of Left Ventricular Noncompaction. <i>American Journal of Cardiology</i> , 2014, 114, 456-462.	0.7	11
147	Rapid automatic segmentation of abnormal tissue in late gadolinium enhancement cardiovascular magnetic resonance images for improved management of long-standing persistent atrial fibrillation. <i>BioMedical Engineering OnLine</i> , 2015, 14, 88.	1.3	11
148	Validation of T2* in-line analysis for tissue iron quantification at 1.5ÅT. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 18, 23.	1.6	11
149	Left atrial dilation in patients with heart failure and preserved ejection fraction: Insights from cardiovascular magnetic resonance. <i>International Journal of Cardiology</i> , 2016, 210, 158-160.	0.8	11
150	Diffusion tensor cardiovascular magnetic resonance with a spiral trajectory: An in vivo comparison of echo planar and spiral stimulated echo sequences. <i>Magnetic Resonance in Medicine</i> , 2018, 80, 648-654.	1.9	11
151	Identification of myocardial diffuse fibrosis by 11 heartbeat MOLLI T1 mapping: averaging to improve precision and correlation with collagen volume fraction. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2018, 31, 101-113.	1.1	11
152	Cardiovascular magnetic resonance predictors of heart failure in hypertrophic cardiomyopathy: the role of myocardial replacement fibrosis and the microcirculation. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 26.	1.6	11
153	Lipoprotein(a) in patients with aortic stenosis: Insights from cardiovascular magnetic resonance. <i>PLoS ONE</i> , 2017, 12, e0181077.	1.1	11
154	Journal of Cardiovascular Magnetic Resonance: Open access in 2008. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2008, 10, 1.	1.6	10
155	Myocardial T2* in Patients with Cardiac Failure Secondary to Iron Overload.. <i>Blood</i> , 2005, 106, 3838-3838.	0.6	10
156	Calibration of Improved T2* Method for the Estimation of Liver Iron Concentration in Transfusional Iron Overload.. <i>Blood</i> , 2009, 114, 2004-2004.	0.6	10
157	Clinical Significance of Partial Anomalous Pulmonary Venous Connections (Isolated and Atrial Septal) Tj ETQq1 1 0.784314 rgBT /Over Imaging, 2021, 14, e012371.	1.3	9
158	Improved Endothelial Function with Combined Chelation Therapy in Thalassemia Major.. <i>Blood</i> , 2006, 108, 1770-1770.	0.6	9
159	Efficacy and Safety of Deferasirox (ExjadeÅ®) in Preventing Cardiac Iron Overload in Î²-Thalassemia Patients with Normal Baseline Cardiac Iron: Results from the Cardiac Substudy of the EPIC Trial. <i>Blood</i> , 2008, 112, 3874-3874.	0.6	9
160	The impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a): Objectives and methods of a randomised controlled trial. <i>Atherosclerosis Supplements</i> , 2015, 18, 103-108.	1.2	8
161	Predictors and Mechanisms of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2020, 136, 140-148.	0.7	8
162	Cardiac T2* MR in patients with thalassemia major: a 10-year long-term follow-up. <i>Annals of Hematology</i> , 2020, 99, 2009-2017.	0.8	8

#	ARTICLE	IF	CITATIONS
163	A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy with Deferoxamine and Deferiprone on Myocardial Iron in Thalassaemia Major Using Cardiovascular Magnetic Resonance.. Blood, 2005, 106, 3655-3655.	0.6	8
164	Continued Improvement and Normalization of Myocardial T2* In Patients with $\beta^2$ -thalassemia Major Treated with Deferasirox (Exjade <sup>®</sup> ) for up to 3 Years. Blood, 2010, 116, 4276-4276.	0.6	8
165	A comparison of adenosine and arbutamine for myocardial perfusion imaging. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 394-400.	3.3	7
166	Combined imaging, computational and histological analysis of a ruptured carotid plaque: A patient-specific analysis. Artery Research, 2010, 4, 59.	0.3	7
167	Burden of Cardiac Siderosis in a Thalassemia-Major Endemic Population: A Preliminary Report From Pakistan. Journal of Pediatric Hematology/Oncology, 2016, 38, 378-383.	0.3	7
168	Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial. Journal of Clinical Lipidology, 2019, 13, 788-796.	0.6	7
169	Diffusion tensor cardiovascular magnetic resonance. Postgraduate Medical Journal, 2019, 95, 433-438.	0.9	7
170	The year in cardiology: imaging. European Heart Journal, 2020, 41, 739-747.	1.0	7
171	Heart Rate as a Marker of Relapse During Withdrawal of Therapy in Recovered Dilated Cardiomyopathy. JACC: Heart Failure, 2021, 9, 509-517.	1.9	7
172	Accelerating Cardiac Diffusion Tensor Imaging With a U <sup>^</sup> Net Based Model: Toward Single Breath <sup>^</sup> Hold. Journal of Magnetic Resonance Imaging, 2022, 56, 1691-1704.	1.9	7
173	Osteoprotegerin and Myocardial Fibrosis in Patients with Aortic Stenosis. Scientific Reports, 2018, 8, 14550.	1.6	6
174	High resolution in <sup>^</sup> vivo DT <sup>^</sup> CMR using an interleaved variable density spiral STEAM sequence. Magnetic Resonance in Medicine, 2019, 81, 1580-1594.	1.9	6
175	A novel cardiovascular magnetic resonance risk score for predicting mortality following surgical aortic valve replacement. Scientific Reports, 2021, 11, 20183.	1.6	6
176	Exposure to Elevated Nitrogen Dioxide Concentrations and Cardiac Remodeling in Patients With Dilated Cardiomyopathy. Journal of Cardiac Failure, 2022, 28, 924-934.	0.7	6
177	MR as a diagnostic tool in heart disease: What is the future?. Magnetic Resonance Materials in Physics, Biology, and Medicine, 1998, 6, 189-190.	1.1	5
178	Carotid plaque rupture. Lancet, The, 2009, 374, 1703.	6.3	5
179	Review of Journal of Cardiovascular Magnetic Resonance 2012. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 76.	1.6	5
180	High prevalence of raised lipoprotein(a) in patients with refractory angina. Global Cardiology Science & Practice, 2015, 2015, 28.	0.3	5

#	ARTICLE	IF	CITATIONS
181	Myocardial deformation assessed by CMR in children after multisystem inflammatory syndrome (MIS-C). International Journal of Cardiology, 2021, 346, 105-106.	0.8	5
182	Fast Fully Automatic Segmentation of the Severely Abnormal Human Right Ventricle from Cardiovascular Magnetic Resonance Images Using a Multi-Scale 3D Convolutional Neural Network. , 2016, , .		4
183	Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a). Antioxidants, 2021, 10, 132.	2.2	4
184	Efficacy and Safety of Deferasirox (Exjade®) in $\hat{I}^2$ -Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.. Blood, 2009, 114, 4062-4062.	0.6	4
185	A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with $\hat{I}^2$ -Thalassemia Major and Iron Overload (CORDELIA).. Blood, 2012, 120, 2124-2124.	0.6	4
186	Deferasirox Compared With Deferoxamine For The Removal Of Cardiac Iron In Patients With $\hat{I}^2$ -Thalassemia Major: 2-Year Data From The Cordelia Extension. Blood, 2013, 122, 1018-1018.	0.6	4
187	Imaging Findings of COVID-19-Related Cardiovascular Complications. Cardiac Electrophysiology Clinics, 2022, 14, 79-93.	0.7	4
188	Performance of Cardiac MRI in Pediatric and Adult Patients with Fontan Circulation. Radiology: Cardiothoracic Imaging, 2022, 4, .	0.9	4
189	Pediatric Cardiac Magnetic Resonance Reference Values for Biventricular Volumes Derived From Different Contouring Techniques. Journal of Magnetic Resonance Imaging, 0, , .	1.9	4
190	Contrast-Enhanced Magnetic Resonance Angiogram of Coronary Artery Bypass Graft Aneurysm. Circulation, 2000, 102, 3148-3148.	1.6	3
191	Review of Journal of Cardiovascular Magnetic Resonance 2011. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 75.	1.6	3
192	In-vivo cardiac DTI: An initial comparison of M012 compensated spin-echo and STEAM. Journal of Cardiovascular Magnetic Resonance, 2016, 18, W19.	1.6	3
193	What is CMR doing for patients today?. European Heart Journal, 2018, 39, 266-270.	1.0	3
194	Calibration of Myocardial T2* Values in Post-Mortem Hearts.. Blood, 2005, 106, 3837-3837.	0.6	3
195	Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years. Blood, 2013, 122, 1016-1016.	0.6	3
196	Spontaneous Coronary Artery Dissection: Insights From Cardiac Magnetic Resonance and Extracoronary Arterial Screening. Circulation, 2022, 145, 555-557.	1.6	3
197	Changes in clinical and imaging variables during withdrawal of heart failure therapy in recovered dilated cardiomyopathy. ESC Heart Failure, 2022, 9, 1616-1624.	1.4	3
198	Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy using cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2010, 12, .	1.6	2

#	ARTICLE	IF	CITATIONS
199	Review of journal of cardiovascular magnetic resonance 2010. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 48.	1.6	2
200	Anomalous drainage of isolated superior caval vein to the left atrium: the oldest reported unrepaired case. Cardiology in the Young, 2017, 27, 1008-1010.	0.4	2
201	Prediction and prevention of heart failure in high-risk elderly patients. European Heart Journal, 2019, 40, 539-541.	1.0	2
202	Diffusion tensor cardiovascular magnetic resonance in hypertrophic cardiomyopathy: a comparison of motion-compensated spin echo and stimulated echo techniques. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2020, 33, 331-342.	1.1	2
203	CMR unveiling the cause of post CoVid-19 infection chest pain. International Journal of Cardiovascular Imaging, 2021, 37, 2025-2026.	0.7	2
204	Left ventricular noncompaction in pediatric population: could cardiovascular magnetic resonance derived fractal analysis aid diagnosis?. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 90.	1.6	2
205	Invasive and Non-Invasive Imaging for Ischaemia with No Obstructive Coronary Artery Disease. Cardiovascular Imaging Asia, 2021, 5, 83.	0.1	2
206	Validation of T2* Technique in Ex-Vivo Myocardial Tissue.. Blood, 2005, 106, 3718-3718.	0.6	2
207	OUP accepted manuscript. European Heart Journal, 2021, , .	1.0	2
208	Development of a cardiovascular magnetic resonance compatible large animal isolated heart model for direct comparison of beating and arrested hearts. NMR in Biomedicine, 2022, , e4692.	1.6	2
209	Magnetic resonance imaging in the assessment of patients with heart failure. Journal of Nuclear Cardiology, 2002, 9, S60-S70.	1.4	1
210	New Publishing Arrangements for JCMR. Journal of Cardiovascular Magnetic Resonance, 2007, 9, 729-729.	1.6	1
211	YI-3â€¦Early cardiac remodelling after pulmonary valve replacement in patients with repaired tetralogy of fallot. Heart, 2016, 102, A26-A26.	1.2	1
212	50â€¦Incremental diagnostic value of cardiovascular magnetic resonance in young adult survivors of sudden cardiac arrest. Heart, 2017, 103, A39-A39.	1.2	1
213	Dâ€¦Perfusion abnormalities in hypertrophic cardiomyopathy: mechanisms and prognostic importance. , 2018, , .		1
214	Cardiovascular Magnetic Resonance to Guide and Monitor the Myocardial Response to Treatment. Circulation: Cardiovascular Imaging, 2019, 12, e010045.	1.3	1
215	A model based on clinical parameters to identify myocardial late gadolinium enhancement by magnetic resonance in patients with aortic stenosis: An observational study. JRSM Cardiovascular Disease, 2020, 9, 204800402092240.	0.4	1
216	Normal values of MAPSE and TAPSE in the paediatric population established by cardiovascular magnetic resonance. International Journal of Cardiovascular Imaging, 2022, 38, 407-409.	0.7	1

#	ARTICLE	IF	CITATIONS
217	Inter-Site Validation of a Single Breath Hold T2* MR Technique for Heart and Liver Iron Measurement.. Blood, 2005, 106, 3830-3830.	0.6	1
218	Association of Liver Iron Concentration Levels with Myocardial T2* Responses in Transfusion-Dependent Thalassemia Major Patients Treated with Deferasirox and Deferoxamine-Extension of Cordelia Study. Blood, 2015, 126, 2155-2155.	0.6	1
219	Myocardial T2* Is Not Affected by the Structural Effects of Myocardial Fibrosis, Ageing or Impaired Left Ventricular Function.. Blood, 2005, 106, 1675-1675.	0.6	1
220	Normalized Left Ventricular Volumes and Function in Thalassemia Major Patients with Normal Myocardial Iron.. Blood, 2005, 106, 2707-2707.	0.6	1
221	Improvement in Right Ventricular Function Following 1 Year of Deferasirox Therapy in Patients with $\beta^2$ -Thalassemia.. Blood, 2009, 114, 5106-5106.	0.6	1
222	Cardiovascular Magnetic Resonance Assessment of Right Ventricular Anatomy and Function. , 2019, , 454-468.e4.		1
223	Nuclear cardiology in clinical practice. British Journal of Hospital Medicine, 1999, 60, 183-186.	0.3	0
224	Unusual Cardiomyopathiesâ€”Role of Cardiac Magnetic Resonance Imaging. , 0, , 251-260.		0
225	Role of delayed enhancement MRI in patients with acute coronary syndrome and unobstructed coronary arteries: reply. European Heart Journal, 2007, 28, 2417-2417.	1.0	0
226	Late gadolinium enhancement in cardiac sarcoidosis predicts ICD implantation and appropriate discharge. Journal of Cardiovascular Magnetic Resonance, 2010, 12, .	1.6	0
227	The predictive value of normal CMR scans in patients with suspected ARVC - an outcomes study. Journal of Cardiovascular Magnetic Resonance, 2010, 12, .	1.6	0
228	Recanalization of coronary chronic total occlusion guided by cardiovascular magnetic resonance imaging and its relation with health outcome measures. Journal of Cardiovascular Magnetic Resonance, 2010, 12, .	1.6	0
229	Prognostic CMR predictors of adverse outcomes in patients with suspected ARVC. Journal of Cardiovascular Magnetic Resonance, 2010, 12, .	1.6	0
230	Response to Letter Regarding Article, â€œRole of Cardiovascular Magnetic Resonance as a Gatekeeper to Invasive Coronary Angiography in Patients Presenting With Heart Failure of Unknown Etiologyâ€• Circulation, 2012, 125, .	1.6	0
231	Use of CMR imaging to assess the effect of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a). Journal of Cardiovascular Magnetic Resonance, 2015, 17, P137.	1.6	0
232	The utility of free-breathing, motion-corrected late gadolinium enhancement for right ventricular fibrosis imaging in congenital heart disease. Journal of Cardiovascular Magnetic Resonance, 2015, 17, P221.	1.6	0
233	P5â€…Aortic dilatation in repaired tetralogy of fallot: Features, determinants and progression. Heart, 2016, 102, A2.2-A3.	1.2	0
234	158â€…NT-pro BNP and Survival in Aortic Stenosis. Heart, 2016, 102, A113.2-A114.	1.2	0

#	ARTICLE	IF	CITATIONS
235	134â€¦Non-invasive Interrogation of Myocardial Disarray in Hypertrophic Cardiomyopathy. Heart, 2016, 102, A96.1-A96.	1.2	0
236	Myocardial T1 and ECV mapping: how we optimise technical aspects of acquisition. Journal of Cardiovascular Magnetic Resonance, 2016, 18, T9.	1.6	0
237	002â€¦Sudden cardiac death risk stratification in patients with mild dilated cardiomyopathy. Heart, 2017, 103, A2.1-A2.	1.2	0
238	CARDIOVASCULAR MAGNETIC RESONANCE IN SURVIVORS OF SUDDEN CARDIAC ARREST: 14 YEAR EXPERIENCE FROM A TERTIARY REFERRAL CENTRE IN THE UNITED KINGDOM. Journal of the American College of Cardiology, 2017, 69, 491.	1.2	0
239	127â€¦Relationship between plasma concentrations of b-type natriuretic peptide and exercise capacity in hypertrophic cardiomyopathy. Heart, 2017, 103, A96-A97.	1.2	0
240	94â€¦Oxidised ldl levels correlate with lipoprotein(a) levels and are reduced by lipoprotein apheresis in a randomised study on patients with refractory angina and raised lipoprotein?(a). Heart, 2017, 103, A69.1-A69.	1.2	0
241	Response by Halliday et al to Letter Regarding Article, "Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients with Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction". Circulation, 2018, 137, 101-102.	1.6	0
242	23â€¦MRI-conditionality has no impact on pacemaker and defibrillator lead parameter changes with MRI at 1.5 t. , 2018, , .		0
243	Assessment of Cardiac Function. , 2019, , 192-207.e4.		0
244	The Effect of Combined Chelation Therapy in the Treatment of Severe Myocardial Iron Loading in Beta Thalassaemia Major.. Blood, 2005, 106, 3836-3836.	0.6	0
245	Plaque Rupture in the Carotid Artery: A Combined Imaging, Computational and Histological Analysis. , 2009, , .		0
246	Impact of Myocardial Iron Loading On Right Ventricular Function.. Blood, 2009, 114, 2012-2012.	0.6	0
247	2â€¦Assessment of the microstructure in recovered dilated cardiomyopathy with diffusion tensor cardiovascular magnetic resonance. , 2018, , .		0
248	Coronary Artery and Sinus Velocity and Flow. , 2019, , 309-324.e3.		0
249	Cardiac Iron Loading and Myocardial T2*. , 2019, , 400-409.e4.		0